ReviewMolecular cancer2025
Orchestrating movement: the role of Caveolin-1 in migration and metastasis.
Review in Molecular cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrative Bulk and Single-Cell Transcriptomic Analysis Identifies a Hypoxia- and Lipid Metabolism-Related Prognostic Signature in Oral Squamous Cell Carcinoma: A Retrospective Study.International journal of molecular sciences · 2026Article
- Loss of Gαq reshapes fibroblast traits and drives tumor-stroma remodeling in oral cancer progression.EMBO reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Cancer metastasis is a complex, multi-step process that accounts for the majority of cancer-related deaths. Cell motility and directional migration are central to these processes. Cell migration’s molecular mechanisms and metastatic disease progression are strongly correlated, and Caveolin-1 (CAV1) is expected to be involved in metastasis based on its role in migrating cells. In early-stage cancers, CAV1 typically suppresses tumour growth by inhibiting cell proliferation and stabilising cellular signalling, and its downregulation or loss is commonly linked to tumour initiation. However, in advanced cancers, CAV1 expression is often upregulated and facilitates tumour progression by enhancing cell migration, invasion, metastasis, and resistance to therapy. Consequently, CAV1 has emerged as a critical mediator in transitioning from localised tumour growth to metastatic spread. However, the context-dependent roles of CAV1 make it difficult to understand its role in metastasis. This review aims to provide a comprehensive overview of the involvement of CAV1 in different modes of cancer cell migration and metastasis. We discuss its molecular functions, context-dependent roles, and interactions with key signalling pathways, including extracellular vesicle signalling, that control cell movement, shedding light on its complex contribution to cancer progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.